1. A Study or Subgroup Apixaban Larsen et al.52 Nielsen et al.53
Subtotal (95%CI)
Heterogeneity: Tau² = 0.01; chi-square = 1.71, df = 1 (P = .19); I² = 42%
Test for overall effect: Z = 1.23 (P = .22)
Dabigatran
Heterogeneity: Tau² = 0.00; chi-square = 0.05, df = 1 (P = .83); I² = 0%
Test for overall effect: Z = 0.68 (P = .50)
Rivaroxaban Ni
elsen et al.53
Heterogeneity: Tau² = 0.00; chi-square = 0.41, df = 1 (P = .52); I² = 0%
Test for overall effect: Z = 2.24 (P = .03)
Test for subgroup differences: chi-square = 6.91, df = 2 (P = .03), I² = 71.0%
log[HR]
0.029
0.199
0.058 -
0.174
0.083 SE
0.08
0.10
0.12
0.06
Weight
56.7%
43.3%
100.0%
19.1%
80.9%
69.2%
30.8%
IV, Random, 95%CI
1.03 [ ]
1.22 [ ]
1.11 [ ]
1.06 [ ]
1.03 [ ]
1.04 [0.9
4-1.15]
0.84 [ ]
0.92 [ ]
0.86 [ ] HR
0.7
0.85 1
1.2
1.5
Favors DOAC
Favors Warfarin

2. B HR HR Study or Subgroup log[HR] SE Weight IV, Random, 95%CI
Apixaban
Larsen et al.52
0.010
0.08
33.3%
1.01 [ ]
Li et al.78 -
0.400
0.06
34.5%
0.67 [ ]
Nielsen et al.53
0.199
0.10
32.2%
1.22 [ ]
Subtotal (95% CI)
100.0%
0.93 [ ]
Heterogeneity: Tau² =
0.10; chi-square = 34.61, df = 2 (P < ); I² = 94%
Test for overall effect: Z = 0.38 (P = .71)
Dabigatran
Larsen et al.52
0.010
0.11
20.8%
1.01 [ ]
Nielsen et al.53
0.029
0.06
79.2%
1.03 [ ]
Subtotal (95% CI)
100.0%
1.03 [ ]
Heterogeneity: Tau² = 0.00; chi-square = 0.02, df = 1 (P = .88); I² = 0%
Test for overall effect: Z = 0
.50 (P = .62)
Rivaroxaban
Larsen et al.52 -
0.223
0.07
71.0%
0.80 [ ]
Nielsen et al.53 -
0.083
0.12
29.0%
0.92 [ ]
Subtotal (95% CI)
100.0%
0.83 [ ]
Heterogeneity: Tau² = 0.00; chi-square = 1.00, df = 1 (P = .32); I² = 0%
Test for overall effect: Z = 2.87 (P = .004)
Test for subgroup differences: chi-square = 6.49, df = 2 (P = .04); I²
= 69,2%
0.5
0.7 1
1.5 2
Favours DOAC
Favours Warfarin

3. C HR HR Study or Subgroup log[HR] SE Weight IV, Random, 95%CI
Apix
aban
Larsen et al.52 -
0.462
0.10
33.3%
0.63 [ ]
Li et al.78 -
0.494
0.04
37.6%
0.61 [ ]
Nielsen et al.53
0.095
0.14
29.2%
1,10 [0,84-1,44]
Subtotal (95% CI)
100.0%
0.73 [ ]
Heterogeneity: Tau² = 0.06; chi-square = 16.73, df = 2 (P = .0002); I² = 88%
Test for overall effect: Z = 2.09 (P = .04)
Dabigatran
Larsen et al.52 -
0.386
0.08
47.5%
0.68 [ ]
Nielsen et al.53 -
0.116
0.05
52.5%
0.89 [ ]
Subtotal (95% CI)
100. 0%
0.78 [ ]
Heterogeneity: Tau
² = 0.03; chi-square = 7.59, df = 1 (P = .006); I² = 87%
Test for overall effect: Z = 1.82 (P = .07)
Rivaroxaban
Larsen et al.52
0.029
0.07
59.8%
1.03 [ ]
Nielsen et al.53
0.174
0.09
40.2%
1.19 [ ]
Subtotal (95% CI)
100.0%
1.09 [ ]
Heterogeneity: Tau² = 0,00; chi-square = 1.54, df = 1 (P = .21); I² = 35%
Test for overall effect: Z =
1.24 (P = .22)
Test for subgroup differences: chi-square = 8.88, df = 2 (P = .01), I² = 77.5%
0.5
0.7 1
1.5 2
Favours DOAC
Favours Warfarin

4. D Study or Subgroup Apixaban Larsen et al.52 Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = .43)
Dabigatran
Avgil et al. <7560
Avgil et al. >7560
Heterogeneity: Tau² = 0.03; chi-square = 3.66, df = 2 (P = .16); I² = 45%
Test for overall effect: Z = 4.93 (P < )
Rivaroxaban
Test for overall effect: Z = 2.13 (P =
.03)
Test for subgroup differences: chi-square = 3.49, df = 2 (P = .17), I² = 42.7%
log[HR] -
0.186
0.635
0.511
0.942
0.415 SE
0.24
0.23
0.12
0.19
Weight
100.0%
24.2%
45.2%
30.6%
IV, Random, 95%CI
.83 [ ]
0.83 [ ]
0.53 [ ]
0.60 [ ]
0.39 [ ]
0.51 [ ]
0.66 [ ] HR
0.2
0.5 1 2 5
Favours DOAC
Favours Warfarin